Dengue fever (DF) is a mosquito-borne disease (Aedes) which can affect two fifths of the world's population. DF infection has a wide
spectrum of symptoms that range from a mild febrile illness to severe outcomes, even death as observed in dengue haemorrhagic
fever (DHF) and dengue shock syndrome (DSS). Importantly, of the 22,000 estimated deaths per year, the large majority are in
children (< 15yrs) where no specific treatment is available.
This MarketVIEW product forecasts the potential commercial value of dengue fever vaccine(s) across endemic and travelers markets to 2030. The model(s)
contain value ($ m) and volume (mio doses) predictions for endemic countries in all age segments in both the public and private
sector. LO and HI forecast scenarios which include expected demand from country selected catch-up campaigns are also detailed
along with discussion of development considerations of the ideal dengue vaccine(s) in light of current pipeline candidates.
THIS PRODUCT IS A SUMMARY PRESENTATION + TWO MODELS
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 20% (from January 2011)
Please review the TERMS and CONDITIONS of purchase.
